Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors
“I am very pleased to welcome Meeta to our Board of Directors. She is an accomplished biopharmaceutical executive with extensive strategic and operational experience and achievements in business development activities. Her work has led to several business transactions and collaborations that brought important, new medicines to patients,” said
“I am thrilled to join Editas Medicine’s Board of Directors at this exciting time when the company is bringing important programs to the clinic. I look forward to being part of this exceptional team and applying my experience to help advance Editas’ innovative CRISPR technology to develop impactful medicines for people living with serious diseases of unmet medical need,” said
About Editas Medicine
As a leading genome editing company,
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the
Cristi Barnett(617) 401-0113 email@example.com Investors Editas Medicine Investor Relations (617) 401-9052 firstname.lastname@example.org
Source: Editas Medicine, Inc.